Oxaliplatin (NSC 266046)

Name: Oxaliplatin (NSC 266046)
Brand: Selleck Chemicals
SKU: S1224
Rating: 5 (111 reviews)

For research use only.

Catalog No.S1224 Synonyms: L-OHP, Eloxatin

111 publications

Oxaliplatin (NSC 266046) Chemical Structure

CAS No. 61825-94-3

Oxaliplatin (NSC 266046, L-OHP, Eloxatin) is a DNA alkylating agent that activates autophagy. Oxaliplatin inhibits DNA synthesis by conforming DNA adducts in RT4, TCCSUP, A2780, HT-29, U-373MG, U-87MG, SK-MEL-2, and HT-144 cells. DMF is recommended for dissolution. Solutions are best fresh-prepared.

Selleck's Oxaliplatin (NSC 266046) has been cited by 111 publications

Cancer Cell, 2020, 37(3):371-386

PubMed: 32109374 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Nat Med, 2018, 24(7):954-960

PubMed: 29808009 ( click the link to review the publication )

Cancer Cell, 2018, 33(6):1094-1110

PubMed: 29805078 ( click the link to review the publication )

Gastroenterology, 2017, 153(4):1082-1095

PubMed: 28625833 ( click the link to review the publication )

Nat Microbiol, 2021, 10.1038/s41564-020-00831-6

PubMed: 33432149 ( click the link to review the publication )

J Cachexia Sarcopenia Muscle, 2021, 10.1002/jcsm.12703

PubMed: 33956410 ( click the link to review the publication )

Mol Cancer, 2021, 20(1):10

PubMed: 33407548 ( click the link to review the publication )

Cancers (Basel), 2021, 13(5)957

PubMed: 33668827 ( click the link to review the publication )

Gigascience, 2021, 10(4)giab026

PubMed: 33871006 ( click the link to review the publication )

Cell Death Dis, 2021, 12(4):337

PubMed: 33795652 ( click the link to review the publication )

Aging (Albany NY), 2021, 13(6):8880-8894

PubMed: 33714949 ( click the link to review the publication )

Cell Prolif, 2021, e13031

PubMed: 33755268 ( click the link to review the publication )

Genet Test Mol Biomarkers, 2021, 25(4):284-292

PubMed: 33877891 ( click the link to review the publication )

Cell Death Differ, 2021, 10.1038/s41418-020-00733-4

PubMed: 33531658 ( click the link to review the publication )

Adv Biol Regul, 2021, S2212-4926(20)30091-9

PubMed: 33451973 ( click the link to review the publication )

ACS Nano, 2020, 28;14(4):5075-5089

PubMed: 32283007 ( click the link to review the publication )

Cancer Res, 2020, 80(21):4815-4827

PubMed: 32907836 ( click the link to review the publication )

J Control Release, 2020, 319:213-221

PubMed: 31899270 ( click the link to review the publication )

J Hematol Oncol, 2020, 1;13(1):40

PubMed: 32357935 ( click the link to review the publication )

Oncogene, 2020, 39(5):987-1003

PubMed: 31591478 ( click the link to review the publication )

Cancer Lett, 2020, 28;476:67-74

PubMed: 32061752 ( click the link to review the publication )

Cancer Lett, 2020, 473:74-89

PubMed: 31904482 ( click the link to review the publication )
Acta Biomater, 2020, S1742-7061(20)30751-0

PubMed: 33388439 ( click the link to review the publication )

Cancers (Basel), 2020, 30;12(5):E1118

PubMed: 32365785 ( click the link to review the publication )

Cancers (Basel), 2020, 12(9)E2580

PubMed: 32927726 ( click the link to review the publication )

Cell Death Dis, 2020, 11(10):822

PubMed: 33009373 ( click the link to review the publication )

Cells, 2020, 9(6):E1474

PubMed: 32560232 ( click the link to review the publication )

Cells, 2020, 9(9)E2110

PubMed: 32948057 ( click the link to review the publication )

Mol Cancer Ther, 2020, 10.1158/1535-7163.MCT-19-0133

PubMed: 32029633 ( click the link to review the publication )

Aging (Albany NY), 2020, 12(23):24424-24440

PubMed: 33291076 ( click the link to review the publication )

Cell Discov, 2020, 21;6:21

PubMed: 32351703 ( click the link to review the publication )

Cancer Cell Int, 2020, 19;20:58

PubMed: 32099531 ( click the link to review the publication )

Cancer Cell Int, 2020, 20:473

PubMed: 33005106 ( click the link to review the publication )

Front Pharmacol, 2020, 11:597520

PubMed: 33343368 ( click the link to review the publication )

Front Pharmacol, 2020, 10;11:252

PubMed: 32210825 ( click the link to review the publication )

Cancer Chemother Pharmacol, 2020, 10.1007/s00280-020-04187-w

PubMed: 33169187 ( click the link to review the publication )

Photochem Photobiol, 2020, 96(2):365-372

PubMed: 31820435 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00425-8

PubMed: 32886306 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00420-z

PubMed: 32870449 ( click the link to review the publication )

Anticancer Res, 2020, 40(7):3659-3667

PubMed: 32620605 ( click the link to review the publication )

Ann Surg Oncol, 2020, 10.1245/s10434-020-08790-2

PubMed: 32632882 ( click the link to review the publication )

BMC Complement Med Ther, 2020, 11;20(1):141

PubMed: 32393373 ( click the link to review the publication )

Int J Cancer, 2020, 10.1002/ijc.33202

PubMed: 32638373 ( click the link to review the publication )

Cell Rep Med, 2020, 1(9):100160

PubMed: 33377131 ( click the link to review the publication )

Theranostics, 2020, 10(5):1981-1996

PubMed: 32104496 ( click the link to review the publication )

BMC Cancer, 2020, 20(1):31

PubMed: 31931755 ( click the link to review the publication )
Sci Rep, 2020, 10(1):11574

PubMed: 32665693 ( click the link to review the publication )

Oncol Lett, 2020, 19(1):663-670

PubMed: 31897182 ( click the link to review the publication )

Mol Genet Genomic Med, 2020, e1409

PubMed: 32748564 ( click the link to review the publication )

Sci Rep, 2020, 10(1):13988

PubMed: 32814794 ( click the link to review the publication )

Onco Targets Ther, 2020, 13:1625-1635

PubMed: 32110058 ( click the link to review the publication )

Exp Ther Med, 2020, 20(2):1415-1422

PubMed: 32742376 ( click the link to review the publication )

Adv Sci (Weinh), 2019, 6(21):1900667

PubMed: 31728273 ( click the link to review the publication )

Cancer Res, 2019, 79(17):4491-4502

PubMed: 31273064 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432.CCR-19-2409

PubMed: 31831554 ( click the link to review the publication )

Biomaterials, 2019, 222:119421

PubMed: 31494503 ( click the link to review the publication )

Oncogene, 2019, 10.1038/s41388-019-1004-2

PubMed: 31530934 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 14;38(1):196

PubMed: 31088567 ( click the link to review the publication )

Cell Death Dis, 2019, 10(8):600

PubMed: 31395855 ( click the link to review the publication )

Biochim Biophys Acta Mol Cell Res, 2019, 1866(10):1533-1543

PubMed: 31301362 ( click the link to review the publication )

Front Oncol, 2019,

PubMed: 31572672 ( click the link to review the publication )

J Mol Cell Biol, 2019, 10.1093/jmcb/mjz032

PubMed: 31065671 ( click the link to review the publication )

Int J Mol Sci, 2019,

PubMed: 31455014 ( click the link to review the publication )

Sci Rep, 2019, 9(1):16647

PubMed: 31719636 ( click the link to review the publication )

Sci Rep, 2019, 9(1):10845

PubMed: 31350465 ( click the link to review the publication )

Chem Biol Interact, 2019, 315:108886

PubMed: 31682804 ( click the link to review the publication )

Cancer Med, 2019, 10.1002/cam4.2764

PubMed: 31823522 ( click the link to review the publication )

Hum Vaccin Immunother, 2019, 10.1080/21645515.2019.1665960

PubMed: 31584324 ( click the link to review the publication )

Oncol Lett, 2019, 17(6):5023-5029

PubMed: 31186713 ( click the link to review the publication )

Oncol Lett, 2019, 5(3):935-942

PubMed: 23426424 ( click the link to review the publication )
Neoplasma, 2019, 66(1):39-45

PubMed: 30509090 ( click the link to review the publication )

Cell Oncol (Dordr), 2019, 10.1007/s13402-019-00471-x

PubMed: 31493144 ( click the link to review the publication )

Nat Commun, 2018, 9(1):2237

PubMed: 29884866 ( click the link to review the publication )

Nat Commun, 2018, 9(1):2434

PubMed: 29934552 ( click the link to review the publication )

Elife, 2018, 7e32838

PubMed: 29417930 ( click the link to review the publication )

Cell Death Discov, 2018, 4:116

PubMed: 30588338 ( click the link to review the publication )

Oncoimmunology, 2018, 7(5):e1424676

PubMed: 29721389 ( click the link to review the publication )

Oncoimmunology, 2018, 7(6):e1431086

PubMed: 29872558 ( click the link to review the publication )

Toxicol Appl Pharmacol, 2018, 356:159-171

PubMed: 30086361 ( click the link to review the publication )

Int J Oncol, 2018, 53(2):844-854

PubMed: 29749542 ( click the link to review the publication )

Transl Oncol, 2018, 11(6):1406-1418

PubMed: 30219696 ( click the link to review the publication )

Cancer Chemother Pharmacol, 2018, 81(2):255-267

PubMed: 29189915 ( click the link to review the publication )

Acta Biochim Biophys Sin (Shanghai), 2018, 50(4):370-380

PubMed: 29471502 ( click the link to review the publication )

Oncotarget, 2018,

PubMed: 29560127 ( click the link to review the publication )

Theranostics, 2018, 8(5): 1312–1326

PubMed: 29507622 ( click the link to review the publication )

Oncotarget, 2018, 9(45):27835-27850

PubMed: 29963241 ( click the link to review the publication )

Sci Adv, 2018, 4(9):eaar4666

PubMed: 30263952 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2017, 114(18):E3729-E3738

PubMed: 28416665 ( click the link to review the publication )

J Cancer, 2017, 8(17):3555-3566

PubMed: 29151941 ( click the link to review the publication )

Mol Cancer Res, 2017, 15(1):15-25

PubMed: 27671335 ( click the link to review the publication )

Sci Rep, 2017, 7(1):10921

PubMed: 28883618 ( click the link to review the publication )

Oncol Rep, 2017, 38(4):2205-2210

PubMed: 28791365 ( click the link to review the publication )

SLAS Discov, 2017, 22(5):507-515

PubMed: 28324660 ( click the link to review the publication )

Cell, 2017, 170(3):548-563

PubMed: 28753429 ( click the link to review the publication )
ACS Cent Sci, 2016, 2(8):545-59

PubMed: 27610416 ( click the link to review the publication )

Cancer Lett, 2016, 380(1):87-97

PubMed: 27322737 ( click the link to review the publication )

Cell Chem Biol, 2016, 23(11):1428-1438

PubMed: 27984028 ( click the link to review the publication )

Mol Cancer Ther, 2016, 15(10):2302-2313

PubMed: 27474148 ( click the link to review the publication )

Mol Pharm, 2016, 13(11):3724-3735

PubMed: 27653969 ( click the link to review the publication )

Biochem Biophys Res Commun, 2016, 478(4):1772-9

PubMed: 27613096 ( click the link to review the publication )

EMBO Mol Med, 2015, 7(10):1350-65

PubMed: 26290450 ( click the link to review the publication )

Oncotarget, 2015, 6(31):31272-83

PubMed: 26418718 ( click the link to review the publication )

Int J Cancer, 2014, 136(4):E51-61

PubMed: 25156627 ( click the link to review the publication )

Ann Surg Oncol, 2014, 21(1):179-88

PubMed: 23907312 ( click the link to review the publication )

J Proteomics, 2014, 113:326-36

PubMed: 25451013 ( click the link to review the publication )

J Biomed Opt, 2014, 19(11):116001

PubMed: 25364948 ( click the link to review the publication )

ACS Chem Biol, 2013, 8(12):2771-7

PubMed: 24093441 ( click the link to review the publication )

Cell Cycle, 2013, 12(18):2960-8

PubMed: 23974105 ( click the link to review the publication )

Optical Methods for Tumor Treatment and Detection, 2013, 10.1117/12.2010730

PubMed: ( click the link to review the publication )

Purity & Quality Control

Choose Selective DNA/RNA Synthesis Inhibitors

Biological Activity

Description

Features

This product is not recommended to be dissolved in dimethylsulfoxide (DMSO).^[9]

Targets

DNA synthesis ^[1]
(RT4, TCCSUP, A2780, HT-29, U-373MG, U-87MG, SK-MEL-2, HT-144 cells)

In vitro

The main mechanism of action of Oxaliplatin is mediated through the formation of DNA–adducts. Oxaliplatin induces primary and secondary DNA lesions that lead to cell apoptosis. ^[1] Oxaliplatin is active against human melanoma cell lines C32 and G361 with IC50 of 0.98 mM and 0.14 mM, respectively. ^[2] Oxaliplatin effectively inhibits bladder carcinoma cell lines RT4 and TCCSUP, ovarian carcinoma cell line A2780, colon carcinoma cell line HT-29, glioblastoma cell lines U-373MG and U-87MG, and melanoma cell lines SK-MEL-2 and HT-144 with IC50 of 11 μM, 15 μM, 0.17 μM, 0.97 μM, 2.95 μM, 17.6 μM, 30.9 μM and 7.85 μM, respectively. ^[4]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
Caco2	MkTKSpVv[3Srb36gRZN{[Xl?	NFjN[IM{OC9zMEFCpO69VQ>?	M3jLe\|E3yqCq	M{fQTmROW09?	MWPhZ5RqfmG2ZYOgUpJnOg>?	Mn3hQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR3NU[0NVUoRjJ2NUW2OFE2RC:jPh?=
Caco2	NV3VSXVmTnWwY4Tpc44hSXO\|YYm=	NYHVbFVCOy9zMD:zNEDPxE1?	MlizNVYhcA>?	MYjEUXNQ	NUmzb4c{cW6lcnXhd4V{KHSqZTDtVm5CKGyndnXsd{Bw\sLiQVvSNWMyNCCQUV:xMEBJVy1zLDDNVnAzNMLiYX7kUXJRO8LiZH;z[U1l\XCnbnTlcpRtgQ>?	M2jOZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NUW2OFE2Lz5{NEW1OlQyPTxxYU6=
Caco2	M2D4eWZ2dmO2aX;uJGF{e2G7	NEPidHU{OMLizszN	M2\xeVI1KGh?	NHfiXJhFVVOR	NFjpZZNqdmS3Y3XzJJRp\SCneIDy[ZN{cW:wIH;mJGhQNTFuIFHLVlFENCCjbnSgUnFQOQ>?	NUnZfXZKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS1OVY1OTVpPkK0OVU3PDF3PD;hQi=>
SW620	M1zOVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUHnWnZ5OTBvN{CgcYcwVA>?	MVuyOE81QC95MjDo		NIXKNoZqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKHSrbXWgZY5lKGSxc3Wg[IVx\W6mZX70JI1idm6nch?=	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDZ2NkOwOUc,OjR4NE[zNFU9N2F-
SW480	NI\vd2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NXPkclhMPDhiaNMg		MVzJR\|UxRTJyLkigeYcwdUx?	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDd{ME[3OUc,OjR5MkC2O\|U9N2F-
HCT116	NF;QR4FHfW6ldHnvckBCe3OjeR?=	MXKyM\|UhyrWP	Ml\BNlQwPDhiaB?=		Mlzmd5VxeHKnc4Pld{B{fXK4aY\pckBuWk6DIHX4dJJme3Orb36=	MoDVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR5NkG0NVEoRjJ2N{[xOFEyRC:jPh?=
HT-29	NFPxZpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlHyNeKh\|ryP	M32yelAuPzJiaB?=		NHnS[FVqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJJRqdWViZHXw[Y5l\W62IH3hco5meg>?	NY\0OWJsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5PVc1PTFpPkK0PVk4PDVzPD;hQi=>
SW480	Mn;MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1PUUVHDqM7:TR?=	MmHoNE04OiCq		M1v5NIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGgeIlu\SCmZYDlcoRmdnRibXHucoVz	MmTwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7OUe0OVEoRjJ2OUm3OFUyRC:jPh?=
HUVEC	MoXsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MX7JR\|UxRTFzLkOwxsDDucLiMT6wNkDPxE1?	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTNyN{S0PEc,OjV\|MEe0OFg9N2F-
HEK293	NYPaR4MyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGjlSolKSzVyPUiuPFLDqMLzwrC1MlU6KM7:TR?=	M2fKWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3M{C3OFQ5Lz5{NUOwO\|Q1QDxxYU6=
HT-29	NFnEd\|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV7qZVRjUUN3ME61NEDPxE1?	MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTNyN{S0PEc,OjV\|MEe0OFg9N2F-
HCT-116	M1rNemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWXXRmhYUUN3ME22MlI1yqEEsdMgNk46PyEQvF2=	NIXnVYQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUOwO\|Q1QCd-MkWzNFc1PDh:L3G+
MCF-7	NU[5V2M5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWLJR\|UxRTF2LkK0xsDDucLiMT64NkDPxE1?	M1njTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3M{C3OFQ5Lz5{NUOwO\|Q1QDxxYU6=
HepG2	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NULER5JKUUN3ME2xOE4zPMLiwsJCpFEvQDJizszN	M4iwOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3M{C3OFQ5Lz5{NUOwO\|Q1QDxxYU6=
A549	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFTDeo1KSzVyPUWxMlA5yqEEsdMgNVAvQTZizszN	NYr3OFFRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWzNFc1PDhpPkK1N\|A4PDR6PD;hQi=>
SGC7901	M3rLemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVfJR\|UxRTJzLkezxsDDucLiMz6wPEDPxE1?	MkXhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV\|MEe0OFgoRjJ3M{C3OFQ5RC:jPh?=
COC1	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1\NXWlEPTB;NE[uNlDDqMLzwrCzMlE1KM7:TR?=	Moe2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV\|MEe0OFgoRjJ3M{C3OFQ5RC:jPh?=
HCT116	NF;2dGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MorTO\|IhcMLi		Ml:3TWM2OD14LkKzxtExNjd3INM1[{9uVA>?	MmfuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV\|NkC2N\|EoRjJ3M{[wOlMyRC:jPh?=
SW480	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NFTsT3I4OiCqwrC=		M4nFR2lEPTB;MUCuO:KyOi5{NjFCuYcwdUx?	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTN4ME[zNUc,OjV\|NkC2N\|E9N2F-
MIAPaCa-2	M2rLVGZ2dmO2aX;uJGF{e2G7	MWeyOgKBkcL3TR?=	NWTuNIo6OjRxNEigbC=>		NWnpUFJCcW6mdXPld{BkdGWjdnHn[UBw\iCSQWLQMEBk[XOyYYPlMVktKGOjc4Dhd4UuQCCjbnSgZ4F{eGG\|ZT2zxsA>	MmD4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2NES5NVQoRjJ3NES0PVE1RC:jPh?=
Panc-1	MVnGeY5kfGmxbjDBd5NigQ>?	NVPnNmlrOjYkgJpCuW0>	NVfwc3F[OjRxNEigbC=>		Mor4bY5lfWOnczDjcIVifmGpZTDv[kBRSVKSLDDjZZNx[XOnLUmsJINie3Cjc3WtPEBidmRiY3HzdIF{\S1\|wrC=	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTR2NEmxOEc,OjV2NES5NVQ9N2F-
MIAPaCa-2	Mk\jRZBweHSxc3nzJGF{e2G7	MlrtNlXjiIoEtV2=	NIey[pQzPCCq		Mle5bY5lfWOnczDhdI9xfG:\|aYOgbY4h[SC\|eX7ldodqe3SrYzDtZY5v\XJiY3;tZolv\WRid3n0bEBYSQ>?	NVnmRo9WRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW0OFQ6OTRpPkK1OFQ1QTF2PD;hQi=>
Panc-1	M13tc2Fxd3C2b4Ppd{BCe3OjeR?=	NFT6N5gzPeLCidM1US=>	MlvuNlQhcA>?		NUnxRYhDcW6mdXPld{BieG:ydH;zbZMhcW5iYTDzfY5memerc4TpZ{Bu[W6wZYKgZ49u[mmwZXSge4l1cCCZQR?=	MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTR2NEmxOEc,OjV2NES5NVQ9N2F-
HPDE	NUSwfIIzS2WubDDWbYFjcWyrdImgRZN{[Xl?	NX2yVIljOjVxNUCg{txO	M1vzSVI1NzR6IHi=		MmPGbY5pcWKrdIOgdJJwdGmoZYLheIlwdiCxZjDQR{Bk\WyuczDpckBiKHO7bnXy[4l{fGmlIH3hco5meiClb33ibY5m\CC5aYToJHdC	MkPHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2NES5NVQoRjJ3NES0PVE1RC:jPh?=
SW1990	MWfD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	MWmyOU82OCEQvF2=	NEKzNmMzPC92ODDo		MoixbY5pcWKrdIOgdJJwdGmoZYLheIlwdiCxZjDQR{Bk\WyuczDpckBiKHO7bnXy[4l{fGmlIH3hco5meiClb33ibY5m\CC5aYToJHdC	NIT3eZo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUS0OFkyPCd-MkW0OFQ6OTR:L3G+
MIAPaCa-2	M2H0dGNmdGxiVnnhZoltcXS7IFHzd4F6	MnfzNlUwPTBizszN	M37YVlI1NzR6IHi=		MkP6bY5pcWKrdIOgdJJwdGmoZYLheIlwdiCxZjDQR{Bk\WyuczDpckBiKHO7bnXy[4l{fGmlIH3hco5meiClb33ibY5m\CC5aYToJHdC	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTR2NEmxOEc,OjV2NES5NVQ9N2F-
Panc-1	MVPD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	MVeyOU82OCEQvF2=	M3;vV\|I1NzR6IHi=		NIHOOFNqdmirYnn0d{Bxem:uaX\ldoF1cW:wIH;mJHBEKGOnbHzzJIlvKGFic4nu[ZJocXO2aXOgcYFvdmW{IHPvcYJqdmWmIIfpeIghX0F?	MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTR2NEmxOEc,OjV2NES5NVQ9N2F-
A549/CDDP	NWL5WIx[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYLJR\|UxRTF6Lk[gxtEhOS5{IN88US=>	NIXTTFQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NU[yOVI1Oyd-MkW2NlUzPDN:L3G+
A549	NIjXOJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlOyTWM2OD13LkigxtEhOC54IN88US=>	M3PheVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NkK1NlQ{Lz5{NU[yOVI1OzxxYU6=
SW480	MkTWSpVv[3Srb36gRZN{[Xl?	MVKxNQKBkcL3Zz;tcC=>	NYjSRpVlOjUkgJno		NY\oNGh{\W6qYX7j[ZMh[2WubIXsZZIh[XW2b4DoZYdq[yCobIX4	NELNT\|k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUe0PVQzOCd-MkW3OFk1OjB:L3G+
SW620	MVXGeY5kfGmxbjDBd5NigQ>?	MUCxNQKBkcL3Zz;tcC=>	MljRNlTjiImq		NGO0dWJmdmijbnPld{Bk\WyudXzhdkBifXSxcHjh[4lkKG[udYi=	M2K4Z\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3N{S5OFIxLz5{NUe0PVQzODxxYU6=
SW480	MUfGeY5kfGmxbjDBd5NigQ>?	NF6zXVAyOOLCidM1[{9udA>?	NYDET2VXOjUkgJno		NWHH[\|hwcW6lcnXhd4V{KEyFMz3JTUBi[2O3bYXsZZRqd25iYX7kJIRm[3KnYYPld{BRPjJiZYjwdoV{e2mxbh?=	M17vNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3N{S5OFIxLz5{NUe0PVQzODxxYU6=
SW620	NH7XZVhHfW6ldHnvckBCe3OjeR?=	NE[wbVkyOOLCidM1[{9udA>?	MXuyOQKBkWh?		M1\vVolv[3KnYYPld{BNSzNvSVmgZYNkfW23bHH0bY9vKGGwZDDk[YNz\WG\|ZYOgVFYzKGW6cILld5Nqd25?	Mn31QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5NEm0NlAoRjJ3N{S5OFIxRC:jPh?=
HT-29	NXniflB1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUDkfHNYUUN3ME21MlIzKM7:TR?=	MkixQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5NkG0O\|koRjJ3N{[xOFc6RC:jPh?=
SNU-175	NVqxN\|AyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkLPTWM2OD1zLkWxJO69VQ>?	NHzBN2c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUe2NVQ4QSd-MkW3OlE1Pzl:L3G+
COLO-320DM	M2q5ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1T1NmlEPTB;NT6zPEDPxE1?	Mn;VQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5NkG0O\|koRjJ3N{[xOFc6RC:jPh?=
DLD-1	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFiwU2FKSzVyPUiuOlUh\|ryP	MoG4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5NkG0O\|koRjJ3N{[xOFc6RC:jPh?=
DiFi	NXnXXXV2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV3sW\|FOUUN3ME2xNE46PSEQvF2=	MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTd4MUS3PUc,OjV5NkG0O\|k9N2F-
HCT-15	M{HqXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MULJR\|UxRThwNkSg{txO	NFLyXVY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUe2NVQ4QSd-MkW3OlE1Pzl:L3G+
SCM-1	NI[zU5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoXvTWM2OD1zNz61JO69VQ>?	M4K4fVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3N{i5NFU4Lz5{NUe4PVA2PzxxYU6=
TMK-1	M33iOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYXJR\|UxRTJ{Lk[g{txO	Mn\XQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5OEmwOVcoRjJ3N{i5NFU4RC:jPh?=
MKN-45	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkLnTWM2OD1zND6wJO69VQ>?	M1HZdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3N{i5NFU4Lz5{NUe4PVA2PzxxYU6=
AGS	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1HPW2lEPTB;MUCuOkDPxE1?	NHzqR409[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUe4PVA2Pyd-MkW3PFkxPTd:L3G+
S3	MkfMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoP4TWM2OD13Mz61JOKyKDFwNTFOwG0>	M4fHSFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OECxNFA4Lz5{NUiwNVAxPzxxYU6=
SiHa	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M13XV2lEPTB;MD64JOKyKDBwMTFOwG0>	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPThyMUCwO{c,OjV6MEGwNFc9N2F-
HT-29	NVzBSWpuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mn\STWM2OD1\|NT62JO69VQ>?	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjByM{C4OUc,OjZyMEOwPFU9N2F-
DLD-1	MlfkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIfoXGRKSzVyPUOyMlIh\|ryP	M{jJPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MECzNFg2Lz5{NkCwN\|A5PTxxYU6=
HT29	NYX1VodET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUnkXVZvUUN3ME22N{DPxE1iwsGgNVg>	M2jjXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MEC0NFg1Lz5{NkCwOFA5PDxxYU6=
MC38	M1nsV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFfDVZpKSzVyPUKzJO69VSEEsTCy	NFzUT3k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkCwOFA5PCd-Mk[wNFQxQDR:L3G+
SW620	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFP6VWFKSzVyPUOuOlgh\|ryP	M3L2S\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MEKzNFg2Lz5{NkCyN\|A5PTxxYU6=
SW480	M4XSR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVfwcZV7UUN3ME2yMlg3KM7:TR?=	M3nmXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MEKzNFg2Lz5{NkCyN\|A5PTxxYU6=
RKO	NVvjN21xT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mmn6TWM2OD1zLkKzJO69VQ>?	MlLYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZyMkOwPFUoRjJ4MEKzNFg2RC:jPh?=
LoVo	MlHSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFi1VY1KSzVyPUGuNkDPxE1?	MkLGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZyMkOwPFUoRjJ4MEKzNFg2RC:jPh?=
KM12	NYnMWHBuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4TTfmlEPTB;ND6zO{DPxE1?	M1nKXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MEKzNFg2Lz5{NkCyN\|A5PTxxYU6=
HCT116p53-	M1;vPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NILIWHJKSzVyPUGuNFgh\|ryP	MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjB{M{C4OUc,OjZyMkOwPFU9N2F-
HCT116	NUnXPYkzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlGxTWM2OD1zLkC0JO69VQ>?	M{XSflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MEKzNFg2Lz5{NkCyN\|A5PTxxYU6=
HCT15	NWHuXlkyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NX22UWFoUUN3ME2xMlQ{KM7:TR?=	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjB{M{C4OUc,OjZyMkOwPFU9N2F-
HT29	NVrZcVdsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnTDTWM2OD1{Lk[5JO69VQ>?	NIDweWc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkCyN\|A5PSd-Mk[wNlMxQDV:L3G+
DLD1	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MY\JR\|UxRTJwMEGg{txO	M3;l[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MEKzNFg2Lz5{NkCyN\|A5PTxxYU6=
Colo205	NFnvSoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1fyfmlEPTB;Mz6zN{DPxE1?	Mmr4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZyMkOwPFUoRjJ4MEKzNFg2RC:jPh?=
BE	NFThXllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVzJR\|UxRTNwM{Og{txO	NWXsPZJoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[wNlMxQDVpPkK2NFI{ODh3PD;hQi=>
CT26	MY\D[YxtKF[rYXLpcIl1gSCDc4PhfS=>	MXG0JI1O	NXzicY5GPDhiaNMg		NIDIU4ll\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgeI8hPTNwMjW=	M4m5UVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MUO3NFEzLz5{NkGzO\|AyOjxxYU6=
CT26	MVvGeY5kfGmxbjDBd5NigQ>?	Mo\BOEBuVQ>?	NVXJZnNuPDhiaNMg		M1TYZ4lv[3KnYYPld{B1cGViZYjwdoV{e2mxbjDs[ZZmdHNib3[gZZV1d3CqYXf5MZJmdGG2ZXSgdJJwfGWrboOsJJN2[2hiYYOgUGM{NUmLLDDC[YNtcW5zIHHu[EBCXEd3	NFKwVmo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkGzO\|AyOid-Mk[xN\|cxOTJ:L3G+
CT26	MlO0SpVv[3Srb36gRZN{[Xl?	NH3ldVk1KG2P	NHrYUlI1QCCqwrC=		NIO0SlRqdmS3Y3XzJIF2fG:yaHHnfS=>	NFzZNFc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkGzO\|AyOid-Mk[xN\|cxOTJ:L3G+
SK-OV-3	NYDuRmtuTnWwY4Tpc44hSXO\|YYm=	MnmzOVAh\|ryPwrC=	NYnlO5p4PDhiaNMg		MUTwdo9ud3SnczDz[Y5{cXSrdnn0fUBw\iCxdnHybYFvKGOjcnPpco9u[SC2bzDOT{Bk\WyuLX3l[IlifGWmIHP5eI9tgXOrcx?=	NHXSN409[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkGzPFY4OSd-Mk[xN\|g3PzF:L3G+
OVCAR-5	NEHON29HfW6ldHnvckBCe3OjeR?=	MV6yNEDPxE4EoB?=	MUWyOIg>		NW\UfFU6eHKxbX;0[ZMhe2Wwc3n0bZZqfHlib3[gc5ZiemmjbjDjZZJkcW6xbXGgeI8hVktiY3XscE1u\WSrYYTl[EBkgXSxbInzbZM>	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjF\|OE[3NUc,OjZzM{i2O\|E9N2F-
PA-1	MUjGeY5kfGmxbjDBd5NigQ>?	MmXQNVAh\|ryPwrC=	NWXjNGkyOjSq		NYLITIc2eHKxbX;0[ZMhe2Wwc3n0bZZqfHlib3[gc5ZiemmjbjDjZZJkcW6xbXGgeI8hVktiY3XscE1u\WSrYYTl[EBkgXSxbInzbZM>	NH:yZ2I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkGzPFY4OSd-Mk[xN\|g3PzF:L3G+
SK-OV-3	MUTGeY5kfGmxbjDBd5NigQ>?	MVe1NEDPxE1?	MYG5OkBp		NFzMVGt2eC2{ZXf1cIF1\XNidHjlJJN1emW\|czDsbYdidmS\|IH\vdkBPUyClZXzsMYFkfGm4YYTpcochemWlZYD0c5J{KGGwZDDUVmFKVCC{ZXPldJRwenN?	MnX1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZzM{i2O\|EoRjJ4MUO4OlcyRC:jPh?=
OVCAR-5	MWTGeY5kfGmxbjDBd5NigQ>?	NV6wbIxwOzBizszN	NHjQ[481QGh?		NWW1[IgyfXBvcnXneYxifGW\|IITo[UB{fHKnc4OgcIlo[W6mczDmc5IhVktiY3XscE1i[3SrdnH0bY5oKHKnY3XweI9zeyCjbnSgWHJCUUxicnXj[ZB1d3K\|	NIXBV3E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkGzPFY4OSd-Mk[xN\|g3PzF:L3G+
PA-1	NH3EWGxHfW6ldHnvckBCe3OjeR?=	NYCxUVY1OTBizszNxsA>	MV[0PIg>		MYj1dE1z\We3bHH0[ZMhfGinIIP0doV{eyCuaXfhcoR{KG[xcjDOT{Bk\WyuLXHjeIl3[XSrbnegdoVk\XC2b4LzJIFv\CCWUlHJUEBz\WOncITvdpM>	MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjF\|OE[3NUc,OjZzM{i2O\|E9N2F-
SK-OV-3	MlKySpVv[3Srb36gRZN{[Xl?	M1jIeVUxKM7:TR?=	MlnvPVYhcA>?		M3L2W5RzcWepZYLld{B1cGVicILv[JVkfGmxbjDv[kB1gXCnIFmgTWZPeyCjbnSgZ4hmdW:taX7ldy=>	NE[yfms9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkGzPFY4OSd-Mk[xN\|g3PzF:L3G+
OVCAR-5	MoHzSpVv[3Srb36gRZN{[Xl?	NGOzRmg{OCEQvF2=	NIKxNI01QGh?		NWDkblRsfHKrZ3fldoV{KHSqZTDwdo9lfWO2aX;uJI9nKHS7cHWgTUBKTk6\|IHHu[EBkcGWvb3vpcoV{	NHP4c\|Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkGzPFY4OSd-Mk[xN\|g3PzF:L3G+
PA-1	MmPySpVv[3Srb36gRZN{[Xl?	MmH0NVAh\|ryPwrC=	MmPkNlRp		NWf2clRifHKrZ3fldoV{KHSqZTDwdo9lfWO2aX;uJI9nKHS7cHWgTUBKTk6\|IHHu[EBkcGWvb3vpcoV{	MlzrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZzM{i2O\|EoRjJ4MUO4OlcyRC:jPh?=
SK-OV-3	NV\mVJBjS2WubDDWbYFjcWyrdImgRZN{[Xl?	NV3UTmZsOC1zMECg{txO	NHnlZlkzPC92OD:3NkBp		M{jjZ4lvcGmkaYTzJINmdGxidnnhZoltcXS7IHnuJIJwfGhidHnt[UBidmRiZH;z[UBl\XCnbnTlcpQhdWGwbnXy	MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjF\|OE[3NUc,OjZzM{i2O\|E9N2F-
OVCAR-5	M1nIe2NmdGxiVnnhZoltcXS7IFHzd4F6	M1;Be\|AuPjBizszN	NXvZNYJFOjRxNEivO\|IhcA>?		M3LIVYlvcGmkaYTzJINmdGxidnnhZoltcXS7IHnuJIJwfGhidHnt[UBidmRiZH;z[UBl\XCnbnTlcpQhdWGwbnXy	NITNcHQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkGzPFY4OSd-Mk[xN\|g3PzF:L3G+
PA-1	NWr2ZoFPS2WubDDWbYFjcWyrdImgRZN{[Xl?	NWi5VZJkOC1{MDFOwG0>	M3S1VFI1NzR6IHi=		MVzpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCrbjDic5RpKHSrbXWgZY5lKGSxc3Wg[IVx\W6mZX70JI1idm6nch?=	M33iVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MUO4OlcyLz5{NkGzPFY4OTxxYU6=
HCT116	MkTTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Ml\wTWM2OD1yLkSxxsDDucLiMD6wNkDPxE1?	MmnjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZzNEi1PVYoRjJ4MUS4OVk3RC:jPh?=
HT29	M1TsSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3PiO2lEPTB;MD64POKhyrIEoECuNkDPxE1?	NILib2g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkG0PFU6Pid-Mk[xOFg2QTZ:L3G+
SNU-387	NHrHeW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYjJR\|UxRTJ3wrFCteKhOi55IN88US=>	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjF4MESyPUc,OjZzNkC0Nlk9N2F-
SNU-475	NYmzS4hjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXLCPXZKUUN3MP-8olMxKM7:TR?=	MmPQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZzNkC0NlkoRjJ4MU[wOFI6RC:jPh?=
Hep-G2	NYTZOYRKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGfwO\|hKSzVyPUGzMlHDqMLzwrCxMlYh\|ryP	MoTuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZzNkC0NlkoRjJ4MU[wOFI6RC:jPh?=
SNU-398	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NG\DN4RKSzVyPU[uOeKhyrIEoEGuNUDPxE1?	NG\OWmY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkG2NFQzQSd-Mk[xOlA1Ojl:L3G+
LoVo	MYHGeY5kfGmxbjDBd5NigQ>?	M3TKZVEwPSEQvF2=	MV[yOE81QCCq		MXfpcoR2[2W\|IITyZY5{[3KrcITpc45idCC{ZYDy[ZN{cW:wIH;mJGRWXC2Q	NFGxbIQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkKwPFUzOyd-Mk[yNFg2OjN:L3G+
HCT116 p53+/+	NYTvVphGTnWwY4Tpc44hSXO\|YYm=	MlHZNU82KM7:TR?=	NHvKTnkzPC92ODDo		Ml36bY5lfWOnczD0doFve2O{aYD0bY9v[WxicnXwdoV{e2mxbjDv[kBFXVRvTh?=	MljmQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ{MEi1NlMoRjJ4MkC4OVI{RC:jPh?=
MDA-MB-231	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3jDNGlEPTB;MkOuNUDDuSByLkGg{txO	NFLtNZc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkKxNVU6OSd-Mk[yNVE2QTF:L3G+
MCF-7	NGmycWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWPJR\|UxRTF3LkSgxtEhOC5\|IN88US=>	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjJzMUW5NUc,OjZ{MUG1PVE9N2F-
SK-BR-3	M2DjZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MonMTWM2OD1\|MT6wJOKyKDBwMTFOwG0>	MlPTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ{MUG1PVEoRjJ4MkGxOVkyRC:jPh?=
LoVo	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NVfVfodIPDhiaNMg		NVvoOm16UUN3ME25OE45OyEQvF2=	M{jzdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4Mk[5O\|U6Lz5{NkK2PVc2QTxxYU6=
HCT116	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M122b\|Q5KGkEoB?=		MV;JR\|UxRTFzLki2JO69VQ>?	M{j5eVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4Mk[5O\|U6Lz5{NkK2PVc2QTxxYU6=
SW480	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NWrPelB3PDhiaNMg		NHPQdmRKSzVyPUGuPFch\|ryP	NH7zSJc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkK2PVc2QSd-Mk[yOlk4PTl:L3G+
CaES-17	NILqdXlEgXSxdH;4bYNqfHliQYPzZZk>	NEjveHUx6oDVMU[wxsDPxE1?	M{LXVFQ5yqCq		MofxTWM2OD13LkZCpOKyyqByLkKg{txO	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjR5NE[5N{c,OjZ2N{S2PVM9N2F-
HKESC-2	MmD2R5l1d3SxeHnjbZR6KEG\|c3H5	Mk\WNQKBmzF4MNMg{txO	Mn75OFjDqGh?		NH;xW41KSzVyPUWuPOKhyrIEoECuOUDPxE1?	MkjSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ2N{S2PVMoRjJ4NEe0Olk{RC:jPh?=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	VEGFR-1 / NRP-1 ; PubMed: 18790786 Mol Cancer Ther HT29 cells were treated with oxaliplatin (0.2 and 2 μmol/L) in 1% MEM-FBS. Western blotting analysis showed that oxaliplatin treatment up-regulated VEGFR-1 and NRP-1 protein expression. p-AKT(Ser473) / AKT / PTEN / p-Src(Tyr416); PubMed: 18790786 Mol Cancer Ther HT29 cells were treated with oxaliplatin for 5, 15, 30, and 60 min. Western blotting showed that oxaliplatin induced Akt activation, with peak phosphorylation occurring at 60 min and decreased PTEN. Phospho-Src increased at 30 min. p-Src(Y418) / p-FAK(Y861) ; PubMed: 19383922 Cancer Res Src and FAK activation by Western blots were determined at various time periods after oxaliplatin treatment (2.5 µM) for HT29 and KM12-L4 cells, and representative of triplicate experiments. Densitometry represents a ratio of the phosphorylated form to th䲧疝Ỵ疞㧀疜膉痘 瘿⟸෕ᾰƌ෕Ð 㺣痖帉痖Ѐ	18790786 19383922
Immunofluorescence	E-cadherin / Vimentin; PubMed: 30787271 Cell Death Dis Silencing ATXN2L reversed oxaliplatin-induced epithelial mesenchymal transition in MGC803 cells. ATXN2L / G3BP1; PubMed: 30787271 Cell Death Dis Under different concentrations and durations of oxaliplatin stimulation, the immunfluorescence staining expressions of ATXN2L and G3BP1 were enhanced by different levels, and ATXN2L coexpressed with G3BP1 in stress granules.	30787271
Growth inhibition assay	Cell viability ; PubMed: 28339092 Oncol Rep Cell viability curve of BGC-823 and MKN-28 cells treated with oxaliplatin at different concentrations.	28339092

In vivo

A weekly i.p. injection of Oxaliplatin at 10 mg/kg to nude mice bearing hepatocellular HCCLM3 tumors significantly reduces tumor volume and apoptotic index. ^[6] Oxaliplatin (5mg/kg, i.v. on days 1, 5 and 9) is active on T-leukemia-lymphoma L40 AKR with T/C of 1.77. Oxaliplatin is also efficient on intracerebrally grafted L1210 leukemia, MA 16-C xenografts, B16 melanoma xenografts, Lewis lung xenografts and C₂₆ colon carcinoma xenografts. ^[7] Oxaliplatin induces impairment of retrograde neuronal transport in mice. ^[8]

Protocol

Cell Research:

^[4]

- Collapse

Cell lines: RT4, TCCSUP, A2780, HT-29, U-373MG, U-87MG, SK-MEL-2 and HT-144 cell lines
Concentrations: ~100 μM
Incubation Time: 48 hours
Method:
The cytotoxicity studies are carried out with the sulforhodamine-B microculture colorimetrie assay. Typically, cells are plated into 96-well plates on day 0 and exposed to Oxaliplatin on day 1; the sulforhodamine-B assay is carried out 48 h after Oxaliplatin exposure. The plates are incubated at 37 °C in 5% CO₂ and 100% relative humidity at all times except when adding Oxaliplatin and during the final assay period. The initial number of cells plated for the assay ranged from 2-20 × 10³ cells/50 /nL/well. The numbers of cells for plating and the drug exposure time are based on pilot studies using the criteria that (a) the cells in control wells are still in the log phase of growth on the day of the assay; (b) the maximum absorbance for the untreated controls on the day of the assay is in the range of 1.0 to 1.5; and (c) cells go through >2 doublings during the drug exposure. Eight wells are used per concentration. The plates are read at 570 and/or 540 nm using a Biotek Instruments model EL309 microplate reader interfaced with an IBM PC-compatible computer. The data are transferred and transformed into a LOTUS 1-2-3 format by the computer program DATALOG, and survival fractions are calculated by comparing the drug treated with control

(Only for Reference)

Animal Research:

^[6]

- Collapse

Animal Models: Human hepatocellular carcinoma xenografts HCCLM3
Dosages: 10 mg/kg
Administration: A weekly i.p. injection
(Only for Reference)

References

- Collapse

Solubility (25°C)

In vitro	Water	3 mg/mL warmed (7.55 mM)
	DMF	Insoluble
	Ethanol	''0.01 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Oxaliplatin (NSC 266046) SDF

Molecular Weight	397.29
Formula	C₈H₁₄N₂O₄Pt
CAS No.	61825-94-3
Storage	2 years 4°C(in the dark) powder
Synonyms	L-OHP, Eloxatin
Smiles	C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2]

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2021-05-17)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04158349	Recruiting	Drug: Oxaliplatin\|Drug: mFOLFIRI	Colorectal Cancer\|Appendiceal Cancer\|Peritoneal Carcinoma	University of Utah	June 11 2020	Phase 1
NCT04003792	Recruiting	Drug: oxaliplatin\|Drug: FOLFIRI Protocol\|Drug: Bevacizumab	Liver Metastasis Colon Cancer	Rabin Medical Center	January 1 2020	Phase 2
NCT03800693	Recruiting	Drug: Fluorouracil\|Drug: Leucovorin\|Drug: Oxaliplatin	Malignant Digestive System Neoplasm	Emory University\|Hematology/Oncology Pharmacy Association\|University of Pittsburgh	March 14 2019	Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
Is it ok to dissolve Oxaliplatin in DMSO?
Answer:
Even though cis-platin is soluble in DMSO, the use of DMSO to dissolve cis– or trans-diamminedichloroplatinum (DDP) in biological studies is strongly discouraged. The DMSO inserts itself into the ligand and inactivates platin-containing compounds. DMF is a much better choice than DMSO.

DNA/RNA Synthesis Signaling Pathway Map

Related DNA/RNA Synthesis Products

SCR7 ^New

SCR7 is a specific DNA Ligase IV inhibitor, which blocks nonhomologous end-joining (NHEJ). It increases the efficiency of HDR-mediated genome editing up to 19-fold using CRISPR/Cas9 in mammalian cells and mouse embryos.
Blasticidin S HCl ^New

Blasticidin S HCl is a nucleoside antibiotic isolated from Stretomyces girseochromogenes, and acts as a DNA and protein synthesis inhibitor, used to select transfected cells carrying bsr or BSD resistance genes.
YK-4-279 ^New

YK-4-279 is a potent inhibitor of EWS-FLI1 binding to RNA helicase A (RHA).
Cisplatin (NSC 119875)

Cisplatin (NSC 119875, Cisplatinum, cis-diamminedichloroplatinum II, CDDP) is an inorganic platinum complex, which is able to inhibit DNA synthesis by conforming DNA adducts in tumor cells. Cisplatin activates ferroptosis and induces autophagy. Solutions are best fresh-prepared.

Features:One of the most widely used and most potent chemotherapeutic agents.
Gemcitabine (LY-188011) HCl

Gemcitabine (LY-188011, NSC 613327) HCl is a DNA synthesis inhibitor with IC50 of 50 nM, 40 nM, 18 nM and 12 nM in PANC1, MIAPaCa2, BxPC3 and Capan2 cells, respectively.

Features:Gemcitabine has been used to treat pancreatic cancer and has demonstrated effective anti-tumor activity.
Bleomycin (NSC125066) sulfate

Bleomycin Sulfate (NSC125066) is a glycopeptide antibiotic and an anticancer agent for squamous cell carcinomas (SCC) with IC50 of 4 nM in UT-SCC-19A cells.
Gemcitabine (LY-188011)

Gemcitabine (LY-188011, NSC 613327), a nucleic acid synthesis inhibitor, is a very potent and specific deoxycytidine analogue, used as chemotherapy. Gemcitabine induces a potent p53-dependent apoptosis.
Fluorouracil (5-Fluorouracil, 5-FU)

Fluorouracil (5-Fluorouracil, 5-FU, NSC 19893) is a DNA/RNA synthesis inhibitor, which interrupts nucleotide synthetic by inhibiting thymidylate synthase (TS) in tumor cells. Fluorouracil induces apoptosis and can be used in the treatment of HIV.
Carboplatin (NSC 241240)

Carboplatin (NSC 241240, JM-8, CBDCA) is a DNA synthesis inhibitor by binding to DNA and interfering with the cell's repair mechanism in A2780, SKOV-3, IGROV-1, and HX62 cells. Solutions are best fresh-prepared.

Features:A DNA synthesis inhibitor.
Cytarabine (U-19920A)

Cytarabine (U-19920A， Cytarabin, Ara-C, Arabinofuranosyl Cytidine, Cytosine β-D-arabinofuranoside, Cytosine arabinoside, NSC 63878, NSC 287459) is an antimetabolic agent and DNA synthesis inhibitor with IC50 of 16 nM in wild-type CCRF-CEM cells. Cytarabine induces autophagy and apoptosis.

Features:The 1st of a series of cancer drugs that alters the sugar component of nucleosides.

Choose Your Country or Region

By Signaling Pathways

By product type

Oxaliplatin (NSC 266046)